Total Payments
$1,084
2020 Payments
$111.41
Companies
7
Transactions
42
Medicare Patients
1,536
Medicare Billing
$331,913
Payment Breakdown by Category
Food & Beverage$1,072 (98.9%)
Education$11.78 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,072 | 40 | 98.9% |
| Education | $11.78 | 2 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $888.15 | 22 | $0 (2020) |
| Allergan Inc. | $104.59 | 13 | $0 (2017) |
| Insulet Corporation | $26.52 | 2 | $0 (2017) |
| Valeritas, Inc. | $22.96 | 2 | $0 (2017) |
| AbbVie, Inc. | $15.09 | 1 | $0 (2019) |
| Abbott Laboratories | $14.84 | 1 | $0 (2017) |
| Acella Pharmaceuticals, LLC | $11.78 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $111.41 | 2 | AstraZeneca Pharmaceuticals LP ($111.41) |
| 2019 | $187.53 | 5 | AstraZeneca Pharmaceuticals LP ($160.66) |
| 2018 | $292.98 | 7 | AstraZeneca Pharmaceuticals LP ($292.98) |
| 2017 | $492.01 | 28 | AstraZeneca Pharmaceuticals LP ($323.10) |
All Payment Transactions
42 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/30/2020 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $77.08 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/24/2020 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $34.33 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/06/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $12.56 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/14/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $94.50 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/12/2019 | AbbVie, Inc. | Synthroid (Drug) | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: Endocrinology | ||||||
| 02/18/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $53.60 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/16/2019 | Acella Pharmaceuticals, LLC | NP Thyroid (Drug) | Food and Beverage | In-kind items and services | $11.78 | General |
| Category: Hyperthyroidism | ||||||
| 06/19/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $10.50 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/03/2018 | AstraZeneca Pharmaceuticals LP | — | Education | In-kind items and services | $6.78 | General |
| 03/28/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $73.43 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/02/2018 | AstraZeneca Pharmaceuticals LP | XIGDUO (Drug) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/01/2018 | AstraZeneca Pharmaceuticals LP | BYDUREON (Drug) | Food and Beverage | In-kind items and services | $99.99 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/08/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $64.11 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/08/2018 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $11.18 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/26/2017 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $4.40 | General |
| Category: NEUROSCIENCE | ||||||
| 09/25/2017 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $4.60 | General |
| Category: NEUROSCIENCE | ||||||
| 09/11/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Education | In-kind items and services | $5.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/08/2017 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: NEUROSCIENCE | ||||||
| 09/08/2017 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $3.75 | General |
| Category: NEUROSCIENCE | ||||||
| 08/28/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $11.30 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/30/2017 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $9.38 | General |
| 06/27/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $73.31 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/23/2017 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $11.13 | General |
| Category: NEUROSCIENCE | ||||||
| 06/09/2017 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.87 | General |
| Category: NEUROSCIENCE | ||||||
| 06/08/2017 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $4.25 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 332 | 1,122 | $269,961 | $75,967 |
| 2022 | 4 | 373 | 1,395 | $339,588 | $89,999 |
| 2021 | 4 | 441 | 1,444 | $357,237 | $96,793 |
| 2020 | 5 | 390 | 974 | $261,496 | $69,153 |
Total Patients
1,536
Total Services
4,935
Medicare Billing
$331,913
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 160 | 939 | $193,612 | $57,136 | 29.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 152 | 163 | $64,690 | $16,159 | 25.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 20 | $11,659 | $2,671 | 22.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 152 | 1,091 | $224,953 | $59,906 | 26.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 148 | 163 | $64,690 | $16,980 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 51 | 119 | $36,783 | $9,711 | 26.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 22 | 22 | $13,162 | $3,402 | 25.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 178 | 1,091 | $224,953 | $60,979 | 27.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 165 | 186 | $73,818 | $19,290 | 26.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 73 | 142 | $43,892 | $12,704 | 28.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 25 | 25 | $14,574 | $3,819 | 26.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 134 | 645 | $132,993 | $37,161 | 27.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 143 | 156 | $61,912 | $17,070 | 27.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 68 | 128 | $39,854 | $9,771 | 24.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 33 | 33 | $19,742 | $3,269 | 16.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $6,996 | $1,883 | 26.9% |
About Dr. Matthew Weiss, DO
Dr. Matthew Weiss, DO is a Geriatric Medicine healthcare provider based in Fenton, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982712717.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Weiss, DO has received a total of $1,084 in payments from pharmaceutical and medical device companies, with $111.41 received in 2020. These payments were reported across 42 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($1,072).
As a Medicare-enrolled provider, Weiss has provided services to 1,536 Medicare beneficiaries, totaling 4,935 services with total Medicare billing of $331,913. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Medicine
- Location Fenton, MI
- Active Since 08/29/2006
- Last Updated 10/07/2025
- Taxonomy Code 207RG0300X
- Entity Type Individual
- NPI Number 1982712717
Products in Payments
- FARXIGA (Drug) $674.38
- BYDUREON (Drug) $170.62
- NAMZARIC (Drug) $75.37
- VRAYLAR (Drug) $29.22
- XIGDUO (Drug) $26.99
- Omnipod (Device) $26.52
- V-GO (Device) $22.96
- Synthroid (Drug) $15.09
- FreeStyle Libre Pro (Device) $14.84
- NP Thyroid (Drug) $11.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.